Pancreatic duct obstruction after pancreaticojejunostomy: implications for early prediction and prevention of long-term pancreatic complications

Abstract

BackgroundPancreatic duct obstructions are common in patients with pancreaticoduodenectomy. However, it is often neglected in follow up. This study was to review the outcomes of pancreatic duct obstruction and explore the prevention of pancreatic duct obstruction.MethodsA retrospective analysis of 78 patients undergoing pancreaticojejunostomy without reccurence of disease within 24 months between 2004 and 2014. Pancreatic duct obstruction and long-term pancreatic complications were analysed.ResultsTwenty-five patients developed pancreatic duct obstruction following pancreaticojejunostomy, 13 of whom were found to have long-term pancreatic complications. The presence of pancreatic duct obstruction and early pancreatic obstruction were associated with long-term pancreatic complications, respectively (p = 0.002, p = 0.002). There are 10 patients with pancreatic duct stent more than 24 months, the postoperative median pancreatic parenchymal thickness in these 10 patients (17.1 mm, range 8.0 to 24.7 mm) was not significantly change than the median in them preoperative (16.4 mm, range 7.2 to 24.7 mm; p = 0.747). All of them have no long-term pancreatic complications, though the difference was not significantly (p = 0.068).ConclusionsEarly pancreatic duct obstruction is associated with postoperative pancreatic long-term complications. Sustained internal pancreatic stent may improve pancreatic duct obstruction.

Risk factors for exocrine pancreatic insufficiency after pancreatic surgery: a systematic review and meta-analysis

“… 27 These possible occurrences may predict long-term pancreatic obstruction after surgery, especially in early pancreatic duct obstruction. 28 Our findings indicate that patients with chronic pancreatitis were at slightly higher risk for developing de novo ExoPI than patients with neoplasms. This may be due to the possibility of fibrosis development in the former.…”

Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design

“…Considering this, there is a substantial group of patients with localized PDAC either medically unfit to undergo surgery and chemotherapy, or both. Additionally, there is a group whom refrain from chemotherapy and surgery because of expected toxicity and adverse events which reasonably occur in higher rates among patients with higher age [6]. These two groups of patients may be sufficiently fit to undergo a short course of stereotactic ablative radiotherapy (SABR).…”

Laparoscopic pancreaticoduodenectomy and laparoscopic pancreaticoduodenectomy with robotic reconstruction: single-surgeon experience and technical notes

“…Duct-to-mucosa PJ is technically challenging, especially in patients with a soft pancreatic texture and small pancreatic duct, even though these are good indications for MIPD. Furthermore, some studies have revealed that the invagination PJ technique is associated with postoperative pancreatic duct obstruction, which might result in pancreatic endocrine and exocrine insufficiency, as well as complications, such as pancreatic stones, acute pancreatitis, and abdominal pain [25]. Bai et al [26] showed that duct-to-mucosa PJ was superior to invagination in maintaining anastomotic patency.…”